Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release.
All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.
Karlowsky
James A
JA
Focus Technologies, Inc., Herndon, Virginia 20171-4603, USA. jkarlowsky@focusanswers.com
Kelly
Laurie J
LJ
Critchley
Ian A
IA
Jones
Mark E
ME
Thornsberry
Clyde
C
Sahm
Daniel F
DF
D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002170:Canada; D017277:Drug Approval; D004351:Drug Resistance; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid